CS
ROIV icon

Credit Suisse’s Roivant Sciences ROIV Stock Holding History

Credit Suisse’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$3.37M Buy
319,592
+6,046
+2% +$65.2K ﹤0.01% 1529
2023
Q4 		$3.52M Buy
313,546
+44,083
+16% +$430K ﹤0.01% 1538
2023
Q3 		$3.15M Sell
269,463
-113,650
-30% -$1.28M ﹤0.01% 1549
2023
Q2 		$3.86M Buy
383,113
+113,633
+42% +$1.02M ﹤0.01% 1504
2023
Q1 		$1.99M Buy
269,480
+18,976
+8% +$156K ﹤0.01% 1871
2022
Q4 		$2M Buy
250,504
+37,644
+18% +$209K ﹤0.01% 1877
2022
Q3 		$685K Sell
212,860
-41,255
-16% -$160K ﹤0.01% 2597
2022
Q2 		$1.03M Buy
254,115
+201,573
+384% +$800K ﹤0.01% 2352
2022
Q1 		$260K Hold
52,542
– – ﹤0.01% 3279
2021
Q4 		$530K Buy
+52,542
New +$437K ﹤0.01% 3771

Other funds holding ROIV

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Credit Suisse's ROIV Position: Q1 2024 in Review

Credit Suisse increased its Roivant Sciences (ROIV) stake by 1.9% in Q1 2024, buying an estimated $65.2K and bringing the position to 319,592 shares worth $3.37M. The position accounts for ﹤0.01% of the portfolio, ranked #1529.

Credit Suisse first reported a position in ROIV in Q4 2021 and has held it in 10 quarters since. The position peaked at $3.86M in Q2 2023. 260 funds tracked by Wall St. Rank hold ROIV as of Q1 2024.

  • Credit Suisse held 319,592 shares of Roivant Sciences worth $3.37M as of Q1 2024.
  • Credit Suisse bought 6,046 Roivant Sciences shares in Q1 2024, an estimated $65.2K.
  • Roivant Sciences made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1529 holding.
  • Credit Suisse first reported a position in Roivant Sciences in Q4 2021 and has held it in 10 quarters since.
  • Credit Suisse's Roivant Sciences position peaked at $3.86M in Q2 2023.
  • 260 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.